CSIMarket
 
Salarius Pharmaceuticals inc   (SLRX)
Other Ticker:  
 
 
Price: $0.5656 $-0.01 -2.415%
Day's High: $0.5954 Week Perf: 9.38 %
Day's Low: $ 0.55 30 Day Perf: -5.34 %
Volume (M): 6 52 Wk High: $ 2.68
Volume (M$): $ 3 52 Wk Avg: $1.11
Open: $0.60 52 Wk Low: $0.50



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 4
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -18
 Cash Flow (TTM) (Millions $) -9
 Capital Exp. (TTM) (Millions $) 0

Salarius Pharmaceuticals Inc
Salarius Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of targeted therapies for pediatric and adult cancers. The company is dedicated to improving the lives of cancer patients through the creation of innovative treatments that address unmet medical needs. Salarius Pharmaceuticals aims to leverage its expertise in epigenetics and gene regulation to develop effective and safe therapies.


   Company Address: 2450 Holcombe Blvd Houston 77021 TX
   Company Phone Number: 804-9144   Stock Exchange / Ticker: NASDAQ SLRX
   SLRX is expected to report next financial results on March 26, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Game-changing Combination Therapies Show Encouraging Results in Hematologic Cancers and Ewing Sarcoma Treatment

Published Wed, Jan 3 2024 1:30 PM UTC

In the world of medical advancements, the quest to find more effective treatments for devastating diseases remains a priority. Salarius Pharmaceuticals, a leading biotechnology company specializing in developing targeted cancer therapies, has recommenced patient enrollment for a Phase 1/2 clinical trial utilizing their groundbreaking drug, Seclidemstat. This innovative trial...

Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc Shows Significant Improvement in Q3 2023 Financial Results, Boosting Long-Term Success Prospects



In our latest analysis, we observe the financial results of Salarius Pharmaceuticals Inc for the third quarter of 2023. Despite not reporting any revenues, the company's operating shortfall of $-2.532185 million indicates an improvement compared to the previous year. As smaller corporations like Salarius Pharmaceuticals strive to establish their revenue streams, their ability to compete efficiently becomes crucial for their long-term success.
Financial Analysis:
Salarius Pharmaceuticals Inc has managed to alleviate its deficit when comparing the third quarter of 2023 with the same period in 2022. During the third quarter of 2022, the company faced an operating shortfall of $-14.488064 million, whereas in 2023, the shortfall reduced to $-2.532185 million. This remarkable improvement signifies the company's commitment to achieving financial stability and suggests positive steps toward reaching profitability.

Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc Surprises Major Pharmaceutical Preparations Sector with Remarkable Turnaround, Slashing Operating Deficit to $-3.97 Million



The Major Pharmaceutical Preparations sector is keenly following Salarius Pharmaceuticals Inc's second-quarter earnings report for 2023, highlighting the company's efforts to enhance cost-effectiveness. The report shows that the emerging growth company has successfully reduced its operating deficit compared to the same period last year, signifying positive changes within the organization.
For the April to June 2023 reporting season, Salarius Pharmaceuticals Inc reported an operating deficit of $-3.971395 million. While the company has not disclosed its top-line figures yet, it is evident that cost-cutting measures have been implemented, leading to more efficient operations. This improvement is notable when compared to the operating deficit of $-4.757967 million in the same three-month period the previous year.

Salarius Pharmaceuticals Inc

Salarius Pharmaceuticals Inc Sees Operating Loss Improve to $6.117 Million in Recent Fiscal Period

The Major Pharmaceutical Preparations industry has been observing and analyzing the first quarter of 2023 earnings, which show that Salarius Pharmaceuticals Inc (SLRX) has had an operating loss of $-5.420663 million. This is a significant decrease from the first quarter of the previous year, and while there has been no mention of the top-line, industry experts believe that the company's productivity during the development period has increased.
It is important to note that despite the operating loss, there has been some relief on the net loss. The deficit has decreased from the same time frame last year, where the shortfall was $-5.341 million as opposed to the first quarter of 2022, where the net loss was $-6.109 million.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com